{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:06:45Z","timestamp":1776949605820,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cllc.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T14:11:51Z","timestamp":1664547111000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial"],"prefix":"10.1016","volume":"24","author":[{"given":"Anna","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.09.009_bib0001","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J."},{"key":"10.1016\/j.cllc.2022.09.009_bib0002","first-page":"270","article-title":"Lung cancer molecular epidemiology in China: recent trends","volume":"3","author":"Zhou","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.009_bib0003","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cncr.24815","article-title":"Implications of key trials in advanced nonsmall cell lung cancer","volume":"116","author":"Bonomi","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2022.09.009_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0006","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0007","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Masters","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0008","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2018.0049","article-title":"Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer","volume":"4","author":"Hong","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0009","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1158\/0008-5472.CAN-06-1951","article-title":"Presence of Epidermal Growth Factor Receptor Gene T790M mutation as a minor clone in non\u2013small cell lung cancer","volume":"66","author":"Inukai","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.cllc.2022.09.009_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cllc.2022.09.009_bib0011","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor\u2013activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.cllc.2022.09.009_bib0012","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ijc.27813","article-title":"Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from na\u00efve Asian NSCLC patients","volume":"132","author":"Yang","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2022.09.009_bib0013","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cllc.2022.09.009_bib0014","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2022.09.009_bib0015","first-page":"7","article-title":"Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.cllc.2022.09.009_bib0016","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.cllc.2022.09.009_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molonc.2014.08.015","article-title":"Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models","volume":"9","author":"Gavine","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0018","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1158\/1078-0432.CCR-18-1189","article-title":"First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity","volume":"25","author":"Gan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cllc.2022.09.009_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0020","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/1759-7714.14429","article-title":"Clinical outcomes of EGFR+\/METamp+\u2009vs. EGFR+\/METamp- untreated patients with advanced non-small cell lung cancer","volume":"13","author":"Peng","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2022.09.009_bib0021","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.18.00177","article-title":"Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor\u2013mutant non\u2013small-cell lung cancer","volume":"37","author":"Lai","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.cllc.2022.09.009_bib0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtho.2019.10.003","article-title":"A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients","volume":"15","author":"Scagliotti","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.09.009_bib0023","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.cllc.2018.03.010","article-title":"MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy","volume":"19","author":"Reis","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2022.09.009_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40364-019-0179-6","article-title":"Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer","volume":"7","author":"Zhang","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.cllc.2022.09.009_bib0025","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jtho.2016.02.021","article-title":"Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring de novo MET amplification","volume":"11","author":"Gainor","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422002054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:12Z","timestamp":1761506052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422002054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1525730422002054"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.09.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}